We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| International Metals Mining Corp | TSXV:IMM | TSX Venture | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.08 | 0.07 | 0.095 | 0 | 21:00:14 |
Hot Features
Premium
Immunotec Inc. (TSX VENTURE:IMM), a Canadian based company and a leader in the
wellness industry (the "Company" or "Immunotec"), today released its second
quarter 2013 financial results for the three- and six- month periods ended 30
April 2013.
"Immunotec's results are testimony to our founders' vision for bringing improved
health and wellness to our product and opportunity customers. We thank our
independent consultants, employees and external partners who collaborate every
day to make this possible." said Mr. Charles L. Orr, Immunotec's Chief Executive
Officer.
Highlights for the second quarter of fiscal 2013
-- Total Revenue for the three-month period reached $12.6M, an increase of
10.6% as compared to the same period in the previous year. Total revenue
in the six-month period reached $24.8M, an increase of 10.4% as compared
to the same period in the previous year.
-- Network sales in the three-month period reached $11.2M, an increase of
9.0% as compared to the same period in the previous year. Network sales
in the six- month period reached $22.4M, an increase of 10.7% as
compared to the same period in the previous year.
-- Selected expenses,(1) defined as administrative, marketing and selling,
quality and development expenses in the three-month period ended 30
April 2013, amounted to $3.0M or 23.9% of total revenues, which compares
favourably to 24.6% for the same period in the previous year. In the
six-month period, these expenses amounted to $5.9M or 23.9% of total
revenues, also comparing favourably to 25.9% the same period of the
previous year.
-- Adjusted EBITDA,(1) in the three-month period ended 30 April 2013
improved to $0.9M or 7.4% of total revenues, compared to $0.2M or 1.6%
of total revenues for the same period in the previous year, a
significant improvement. For the six-month period, Adjusted EBITDA(1)
amounted to $1.8M or 7.1% of total revenues, also a significant
improvement.
-- Net profit for the three-month period ended 30 April 2013 amounted to
$0.7M; a significant improvement over a net loss of $0.1M for the same
period in the previous year. For the six-month period ended 30 April
2013, net profit amounted to $1.2M, also a significant improvement over
a loss of $0.1M in the same period in the previous year.
(1) Refer to the non-GAAP financial measures section of Management's
Discussion and Analysis.
About Immunotec Inc.
Immunotec is a world-class business opportunity supported by unique,
scientifically proven products that improve wellness. Headquartered with
manufacturing facilities near Montreal, Canada, the Company also has
distribution capacities to support its commercial activities in Canada and
internationally to the United States, Mexico, Europe and the Caribbean.
The Company files its consolidated financial statements, its management and
discussion analysis report, its press releases and such other required documents
on the SEDAR database at www.sedar.com and on the Company's website at
www.immunotec.com. The common shares of the Company are listed on the TSX
Venture Exchange under the ticker symbol IMM.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS: Certain statements contained in
this news release are forward-looking and are subject to numerous risks and
uncertainties, known and unknown. For information identifying known risks and
uncertainties and other important factors that could cause actual results to
differ materially from those anticipated in the forward-looking statements,
please refer to the heading Risks and Uncertainties in Immunotec's most recent
Management's Discussion and Analysis, which can be found at www.sedar.com.
Consequently, actual results may differ materially from the anticipated results
expressed in these forward-looking statements.
SUPPLEMENTAL INFORMATION
Immunotec Inc.
Interim Consolidated Statements of Financial Position
30 April 31 October
2013 2012
(Canadian dollars) $ $
----------------------------------------------------------------------------
----------------------------------------------------------------------------
ASSETS
Current assets
Cash 3,364,901 3,779,089
Trade and other receivables 1,308,887 1,688,279
Inventories 3,205,946 2,601,079
Prepaid expenses 478,595 374,774
----------------------------------------------------------------------------
8,358,329 8,443,221
Non-current assets
Property, plant and equipment 5,833,889 5,931,470
Intangible assets 1,407,804 1,621,830
Goodwill 833,559 833,559
Other non- current assets 3,824,319 3,102,151
----------------------------------------------------------------------------
11,899,571 11,489,010
----------------------------------------------------------------------------
20,257,900 19,932,231
----------------------------------------------------------------------------
----------------------------------------------------------------------------
LIABILITIES
Current liabilities
Bank indebtedness - 5,000
Payables 1,597,624 1,545,310
Accrued liabilities 3,121,910 3,151,212
Provisions 233,488 491,776
Deferred revenue and customer deposits 476,840 630,240
Income taxes 28,596 54,859
Current portion of long- term debt 119,246 117,120
----------------------------------------------------------------------------
5,577,704 5,995,517
Long- term debt 1,902,031 1,964,336
----------------------------------------------------------------------------
7,479,735 7,959,853
----------------------------------------------------------------------------
EQUITY
Share capital 3,448,285 3,462,503
Contributed surplus 13,223,374 13,259,401
Accumulated other comprehensive income (151,266) 179,531
Deficit (3,742,228) (4,929,057)
----------------------------------------------------------------------------
12,778,165 11,972,378
----------------------------------------------------------------------------
20,257,900 19,932,231
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Immunotec Inc.
Interim Consolidated Statements of Income (Loss)
For the three-and six-month periods ended 30 April
Three months Six months
2013 2012 2013 2012
(Canadian dollars except
for the number of
shares) $ $ $ $
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Revenues
Network sales 11,200,095 10,277,123 22,400,589 20,238,165
Other revenue 1,430,248 1,142,964 2,409,113 2,225,090
----------------------------------------------------------------------------
12,630,343 11,420,087 24,809,702 22,463,255
Cost of sales
Cost of goods sold 2,231,194 1,935,261 4,219,646 3,791,383
Sales incentives -
Network 5,596,762 5,407,413 10,978,737 10,371,660
Other variable costs 992,357 1,088,149 2,067,599 2,037,160
----------------------------------------------------------------------------
Margin before expenses 3,810,030 2,989,264 7,543,720 6,263,052
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Expenses
Administrative 1,536,284 1,378,453 2,975,830 2,999,778
Marketing and selling 1,256,541 1,248,505 2,495,615 2,405,769
Quality and
development costs 225,685 183,460 452,720 406,133
Depreciation and
amortization 219,924 223,658 440,596 463,262
Other expenses 16,063 11,706 20,514 21,847
----------------------------------------------------------------------------
Operating income (loss) 555,533 (56,518) 1,158,445 (33,737)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Net finance expenses
(income) (267,745) 124,857 (335,619) 80,373
----------------------------------------------------------------------------
Profit (loss) before
income taxes 823,278 (181,375) 1,494,064 (114,110)
Income taxe expense
(recovery)
Current 4,417 13,298 5,509 15,455
Deferred 160,285 (85,747) 301,726 (27,047)
----------------------------------------------------------------------------
Net profit (loss) 658,576 (108,926) 1,186,829 (102,518)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Total basic and diluted
net profit (loss)
common per share 0.01 (0.00) 0.02 (0.00)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Weighted average number
of common shares
outstanding during the
period
Basic and diluted 69,681,982 69,994,300 69,767,670 69,994,300
----------------------------------------------------------------------------
Immunotec Inc.
Interim Consolidated Statements of Cash Flows
For the six-month periods ended 30 April
2013 2012
(Canadian dollars) $ $
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Operating activities
Net profit (loss) 1,186,829 (102,518)
Adjustments for:
Depreciation 197,712 185,685
Amortization 242,884 277,577
Unrealized foreign exchange differences (331,625) (46,253)
Net interest expense on finanical
liabilities measured at amortized cost 37,697 39,734
Deferred income taxes 301,726 (27,047)
Share- based compensation 20,514 21,847
Interest paid (37,697) (42,129)
Interest received - 2,395
----------------------------------------------------------------------------
Cash prior to working capital variation 1,618,040 309,291
Net change in non- cash working capital (1,649,133) 422,569
----------------------------------------------------------------------------
Net cash (used in) provided by operating
activities (31,093) 731,860
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Investing activities
Additions to property, plant and equipment (77,907) (314,823)
Additions to intangible assets (27,423) (83,057)
----------------------------------------------------------------------------
Net cash used in investing activities (105,330) (397,880)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Financing activities
Bank indebtedness (5,000) -
Reimbursement of long- term debt (60,179) (55,982)
Repurchase of shares (70,759) -
Reimbursment of other liability - (200,203)
----------------------------------------------------------------------------
Net cash used in financing activities (135,938) (256,185)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Net (decrease) increase in cash during the
period (272,361) 77,795
Cash - Beginning of the period 3,779,089 2,561,969
Effect of foreign exchange rate fluctuations
on cash (141,827) (13,627)
----------------------------------------------------------------------------
Cash - End of the period 3,364,901 2,626,137
----------------------------------------------------------------------------
----------------------------------------------------------------------------
FOR FURTHER INFORMATION PLEASE CONTACT:
Immunotec Inc.
Patrick Montpetit
Chief Financial Officer
(450) 510-4527
www.immunotec.com
1 Year International Metals Min... Chart |
1 Month International Metals Min... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
